HHS more optimistic on ACA enrollment than financial analysts

HHS has estimated 13.8 million people will purchase coverage on Affordable Care Act (ACA) insurance exchanges during the next open enrollment period.

The estimate is above what Standard and Poor’s (S&P's) predicted in its Oct. 13 analysis. It expects 11.7 million and 13.3 million people to buy a plan during open enrollment, with as few as 10.2 million people maintaining coverage throughout 2015 as part of a “significant slowdown” in marketplace growth.

“We’re confident that millions of Americans will choose to enroll when they learn that quality, affordable health insurance is within reach,” HHS Secretary Sylvia Burwell said. “We believe 13.8 million sign-ups during the upcoming Open Enrollment will help keep driving down the national uninsured rate, which is already the lowest in our nation’s history.”

The 13.8 million sign-ups would be an increase of 1.1 million over 2016 open enrollment. The agency’s effectuated enrollment estimate was also above S&P’s at 11.4 million.

The gains, Burwell said, could come from several populations, like the estimated 2.5 million off-exchange customers eligible for subsidies if they used the ACA marketplace. The agency has also detailed several new efforts to reach out to younger, healthier customers this year.

“Of course, the biggest opportunity we have to strengthen the marketplace with a bigger, healthier risk pool is right in front of usthis upcoming open enrollment,” Burwell said. "This is the last open enrollment for this administration. We want to make it count."

S&P had factored these efforts into its analysis, while warning enrollment could fall even lower than its estimate if fewer subsidized customers than expected re-enroll for 2017. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.